MedPath

Taisho Pharmaceutical R&D, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:0
Completed:7

Trial Phases

2 Phases

Phase 1:6
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (75.0%)
Phase 2
2 (25.0%)

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: TS-142 Placebo
First Posted Date
2020-07-09
Last Posted Date
2021-02-10
Lead Sponsor
Taisho Pharmaceutical R&D Inc.
Target Recruit Count
28
Registration Number
NCT04464239
Locations
🇺🇸

PPD Phase I unit, Austin, Texas, United States

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: TS-161 Placebo
First Posted Date
2019-04-18
Last Posted Date
2020-02-28
Lead Sponsor
Taisho Pharmaceutical R&D Inc.
Target Recruit Count
70
Registration Number
NCT03919409
Locations
🇺🇸

PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale, California, United States

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2018-11-19
Last Posted Date
2018-11-19
Lead Sponsor
Taisho Pharmaceutical R&D Inc.
Target Recruit Count
33
Registration Number
NCT03746067
Locations
🇺🇸

PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale, California, United States

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2018-11-15
Last Posted Date
2018-11-15
Lead Sponsor
Taisho Pharmaceutical R&D Inc.
Target Recruit Count
59
Registration Number
NCT03742791
Locations
🇺🇸

PAREXEL - Early Phase Clinical Unit-Los Angeles, Glendale, California, United States

Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
Other: Ketamine
First Posted Date
2017-05-05
Last Posted Date
2018-04-30
Lead Sponsor
Taisho Pharmaceutical R&D Inc.
Target Recruit Count
63
Registration Number
NCT03141658
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath